LBA2Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC)
Zhou, C, Lu, Y, Kim, S-W, Reungwetwattana, T, Zhou, J, Zhang, Y, He, J, Yang, J-J, Cheng, Y, Lee, S H, Bu, L, Xu, T, Yang, L, Wang, C, Morcos, P N, Mitry, E, Li, ZVolume:
29
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy483.001
Date:
November, 2018
File:
PDF, 88 KB
english, 2018
File converter
More search results
More benefits 
